Organisation paid for research Program year 2025 Source: CMS Open Payments

Bowden Eye & Associates

Neither a doctor nor a teaching hospital

Research payments

$224,152

64 payments

Through program year 2025, Bowden Eye & Associates is reported as receiving $224,152 in research payments, across 64 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $6,480 7
2024 Research $681 19
2023 Research $3,960 1
2022 Research $5,834 3
2021 Research $145,589 29
2020 Research $61,609 5

Breakdown

Who paid Research payments · program years 2020–2025
  1. Bausch Health US, LLC $181,129 24 payments
  2. Sun Pharmaceutical Industries Inc. $35,862 14 payments
  3. Oyster Point Pharma, Inc. $3,600 2 payments
  4. Dompe Farmaceutici S.p.A. $2,880 5 payments
  5. Argenx US, Inc. $681 19 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3, Multi-Center, Randomized, Double- Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (GOBI) $134,880 7 payments
  2. A Phase 3, Multi-Center, Open-Label, Single-Arm Extension Clinical Trial to Assess the Extended Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects who Completed Trial NVU-003 (SEECASE-2 OLE) $46,249 17 payments
  3. Effect of Cequa in Subjects With Dry Eye Disease $35,862 14 payments
  4. OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) $3,000 1 payment
  5. A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of DFL24498 HCl Eye Drop Solution Versus Vehicle in Adult Participants with Atopic Keratoconjunctivitis (AKC) $2,880 5 payments
  6. A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease $681 19 payments
  7. Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) $600 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record